Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland

201621 citationsJournal Article

Authors

This cost-utility analysis showed vortioxetine to be a good alternative for MDD patients switching therapy in Finland.

Good health and well-being

Published in: Expert Review of Pharmacoeconomics & Outcomes Research

Volume 17, Issue 3, pp. 293-302

Field-Weighted Citation Impact: 1.84